About the Disease

Degenerative arthritis is a disease caused by bones or tendons at joints damaged by gradual or degenerative transformation of cartilage that protects joints. Its symptoms include swelling and pain. The most common initial symptom is local pain around the joints where the arthritis occurred. It is different from rheumatoid arthritis in that it does not cause symptoms that affect the entire body. At first, pain gets worse when moving the affected joint. However, the pain may persist regardless of movement once it progresses further. Other symptoms include decreased scope of joint movement, edema, tenderness around joints. Fricative sound may be felt one the joint surfaces become uneven due to loss and transformation of cartilage.

Cartilage is a very unique tissue without any vessel or nerve. Once damaged, it cannot be fully restored. Despite extensive researches in the area, medications so far only alleviate the symptoms, by controlling pain and improving bodily functions and the patients’ quality of living. No treatment has been developed that effectively treats cartilage loss. Degenerative arthritis is commonly treated with correction of living habits, pain killers, coupled with joint injection of non-steriopid antiflammatory medicine or steroid/hyaluronic acid lubricant. When the pain becomes worse, joint packing (hip/shoulder joint) or joint replacement (hip/knee joint) must be performed to improve the patient’s living quality. There are a variety of treatments currently used, but none of them offer fundamental treatment through joint renewal.

조인트스템

About JointStem

The name JointStem is a combination of Joint and Stem, the latter referring to stem cell. It is an autologous stem cell-based medicine, injected into the glenoid cavity of degenerative arthritis patients to renew their cartilage, alleviate pain, and improve joint functions.

These effects are based on the mechanism of JointStem, which directly renews damaged cartilage, or helps cartilage renewal through various nutrients secreted from JointStem.

Clinical Test Result

In accordance with the Phase 1/2 Clinical Test Plan approved by the Food and Drug Administration, the Orthopedics Department of Boramae Hospital in Seoul conducted clinical tests on knee degenerative arthritis patients. JointStem was tested for its drug fastness and safety while increasing the dosage, to determine the optimal dosage. 9 test subjects (patients) were selected for injection of the optimal dosage and assessment of its effects. Through the 6-month clinical test, the drug fastness and safety of JointStem were verified. On twelve patients injected with the optimal dosage, significant improvement was observed across various clinical indicators that comprehensively assess knee functions and pain (WOMAC, KSCRS, VAS). Above all, cartilage renewal was observed on all 12 patients through MRI and arthroscopy.